NASDAQ : ONC
BeOne Medicines AG — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 370.33 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 42.11B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 42.11B |
| Enterprise Value | 39.06B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 113.70M |
| Shares Change (YoY) | +8.01% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 4.10% |
| Owned by Institutions (%) | 52.87% |
| Float | 80.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 66.29 |
| Forward PE | 45.99 |
| PS Ratio | 6.87 |
| Forward PS | 5.82 |
| PB Ratio | 8.09 |
| P/TBV Ratio | 8.24 |
| P/FCF Ratio | 31.66 |
| P/OCF Ratio | 28.37 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 59.57 |
| EV / Sales | 6.37 |
| EV / EBITDA | 36.45 |
| EV / EBIT | 42.31 |
| EV / FCF | 29.36 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.40 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.86 |
| Debt / FCF | 1.54 |
| Interest Coverage | 7.97 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 14.66% |
| Return on Assets (ROA) | 7.46% |
| Return on Invested Capital (ROIC) | 33.62% |
| Return on Capital Employed (ROCE) | 13.08% |
| Weighted Average Cost of Capital (WACC) | 7.45% |
| Revenue Per Employee | $510,747 |
| Profits Per Employee | $54,642 |
| Employee Count | 12,000 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 1.10 |
Taxes
| Measure | Value |
|---|
| Income Tax | 212.37M |
| Effective Tax Rate | 24.46% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +17.62% |
| 50-Day Moving Average | 363.15 |
| 200-Day Moving Average | 324.91 |
| Relative Strength Index (RSI) | 52.68 |
| Average Volume (20 Days) | 366,875 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.79M |
| Short Previous Month | 1.93M |
| Short % of Shares Out | 2.21% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.13B |
| Gross Profit | 5.45B |
| Operating Income | 923.10M |
| Pretax Income | 868.08M |
| Net Income | 655.71M |
| EBITDA | 1.07B |
| EBIT | 923.10M |
| Earnings Per Share (EPS) | $5.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.10B |
| Total Debt | 2.05B |
| Net Cash | 3.05B |
| Net Cash Per Share | $26.81 |
| Equity (Book Value) | 5.17B |
| Book Value Per Share | 45.78 |
| Working Capital | 5.10B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.48B |
| Capital Expenditures | -153.87M |
| Depreciation & Amortization | 148.51M |
| Net Borrowing | 108.37M |
| Free Cash Flow | 1.33B |
| FCF Per Share | $11.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | 88.89% |
| Operating Margin | 15.06% |
| Pretax Margin | 14.16% |
| Profit Margin | 10.70% |
| EBITDA Margin | 17.48% |
| EBIT Margin | 15.06% |
| FCF Margin | 21.70% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.01% |
| Shareholder Yield | -8.01% |
| Earnings Yield | 1.51% |
| FCF Yield | 3.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $437.57 |
| Price Target Difference | 18.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 18.04% |
| EPS Growth Forecast (3Y) | 82.45% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.65 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |